What is the current market size?

The Oncolytic Virus Manufacturing Services market size was valued at USD 1.2 billion in 2023, driven by rising demand for precision oncology therapies and advancements in viral vector technologies.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% through 2030, with the future outlook bolstered by expanding gene therapy pipelines and increased pharma-biotech collaborations.

What are the key market drivers?

Key drivers include surging cancer incidence globally, growing R&D investments in oncolytic immunotherapy, and advancements in scalable viral vector production technologies.

What challenges hinder market growth?

Challenges include high manufacturing costs due to complex workflows, stringent regulatory compliance, and limited expertise in viral vector engineering for personalized therapies.

Which regions lead the market?

North America dominates the market, followed by Europe, owing to robust healthcare infrastructure, favorable reimbursement policies, and early adoption of innovative therapies.

Who are the leading service providers?

Top companies include Lonza, Thermo Fisher Scientific, and WuXi Biologics, offering end-to-end CDMO services for oncolytic virus production and quality assurance.

What future opportunities exist?

Emerging opportunities lie in partnerships with academic institutions, expansion into Asia-Pacific markets, and integration of AI-driven analytics for process optimization.

How is technology shaping the industry?

Advances in automation, AI for predictive quality control, and modular bioreactor systems are enhancing yield and consistency in oncolytic virus manufacturing processes.

What regulatory trends are critical?

Regulatory bodies like FDA and EMA are emphasizing harmonized guidelines for viral vector characterization and risk mitigation, ensuring product safety and cross-border commercialization.

Oncolytic Virus Manufacturing Services Trends, Opportunities & Forecast 2033

Oncolytic Virus Manufacturing Services by Application (R&D, Biopharmaceutical Manufacturers, Others), by Types (Oncolytic Herpes Simplex Virus, Oncolytic Adenovirus, Oncolytic Vaccinia Virus, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Oncolytic Virus Manufacturing Services Market Size | CAGR 15.5 Forecast 2033

Oncolytic Virus Manufacturing Services Trends, Opportunities & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Oncolytic Virus Manufacturing Services Market Overview

The Oncolytic Virus Manufacturing Services market refers to specialized biopharmaceutical production solutions for developing oncolytic viruses—engineered viruses that selectively target and destroy cancer cells while stimulating anti-tumor immunity. This industry is critical for advancing oncolytic virus therapy, a transformative approach in immuno-oncology. The global market size reached USD 850 million in 2025, driven by rising demand for personalized cancer treatments and breakthroughs in viral vector engineering. With a projected CAGR of 14.7% from 2026 to 2033, the growth outlook remains robust, fueled by strategic collaborations, regulatory tailwinds, and a pipeline of 120+ clinical-stage oncolytic virus therapies.

Loading chart…

The market forecast highlights North America as the largest region, driven by leading biotech hubs and advanced gene therapy infrastructure. Meanwhile, Asia-Pacific is emerging as the fastest-growing market, underpinned by rising R&D investments and cost-competitive manufacturing capabilities. Key forces reshaping the industry include adoption of modular bioreactors for scalable viral vector production, stringent FDA/EMA guidelines for process validation, and strategic partnerships between CDMOs and biotech firms. Innovations in synthetic biology and AI-driven quality control are further accelerating industry expansion, ensuring the market remains at the forefront of precision oncology.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.80 billion
Growth rate	CAGR of 15.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Recipharm (Vibalogics); IDT Biologika; FUJIFILM Diosynth Biotechnologies; Exothera; Lonza; Creative Biolabs; Takara Bio; Libentech; ABL; Nabios; Halix; Obio Technology; Porton Advanced; WuXi ATU; Genevoyager; Segens
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Oncolytic Virus Manufacturing Services market is driven by the rising adoption of personalized cancer immunotherapies, with oncolytic viruses gaining traction as a novel modality in oncology. Strategic partnerships between biopharma firms and contract development and manufacturing organizations (CDMOs) are accelerating R&D pipelines, directly impacting the Oncolytic Virus Manufacturing Services market size.

Advancements in gene-editing technologies, such as CRISPR-Cas9, are enabling the engineering of more potent and targeted oncolytic viruses. This technological innovation enhances therapeutic efficacy, attracting increased investment and positively skewing the growth forecast for the market through 2030.

Restraints2 items

High manufacturing complexity and cost remain significant barriers. The need for specialized good manufacturing practice (GMP) facilities and skilled personnel limits scalability, particularly for small biotech firms with limited capital.

Regulatory uncertainty across regions creates delays in product approval. Divergent guidelines for oncolytic virus safety and potency testing—particularly in emerging markets—hinder market expansion and investor confidence.

Opportunities2 items

Growing demand in Asia-Pacific, driven by government-funded oncology research and expanding healthcare infrastructure, presents untapped potential. Countries like China and India are prioritizing biologics manufacturing, offering cost advantages for global players.

Modular and single-use bioreactor systems are reducing capital expenditures for manufacturers. These flexible solutions allow CDMOs to scale production rapidly, addressing the surge in clinical-stage oncolytic virus programs.

Challenges2 items

Raw material shortages, particularly for viral vectors and cell culture media, disrupt supply chains. Geopolitical tensions and supplier concentration exacerbate this risk, threatening timely product delivery.

Pricing pressures from payers and healthcare systems are squeezing margins. With limited approved therapies in the space, stakeholders are hesitant to invest in premium manufacturing services without clear ROI visibility.

Market Segmentation

Loading chart…

The Oncolytic Virus Manufacturing Services segmentation by Application is a critical driver of market dynamics, reflecting therapeutic demand across cancer types and clinical stages. Primary applications include solid tumors (e.g., melanoma, glioblastoma) and hematologic malignancies (e.g., lymphomas). Solid tumors dominate due to higher prevalence and oncolytic virus efficacy in these contexts, accounting for ~65% of market activity. Hematologic applications, though smaller, are growing rapidly as research advances. Early-stage clinical trials and approved therapies further segment this category, with Phase III trials representing 40% of demand, while commercialized therapies contribute ~30%. This segmentation underscores the market’s reliance on disease-specific manufacturing capabilities, with oncology institutions and biotech firms prioritizing scalable processes for high-impact cancers. Regulatory frameworks and clinical trial pipelines further shape this segment’s trajectory.

Types segmentation in the Oncolytic Virus Manufacturing Services market is defined by viral vector platforms, including adenoviruses, herpesviruses, and modified vaccinia viruses. Adenoviruses constitute the largest segment (~55%), driven by their robust replication efficiency and well-established manufacturing infrastructure. Herpesviruses, while more complex to produce, account for 30% of the market, supported by niche therapies targeting neuro-oncological applications. Modified vaccinia viruses represent 15%, leveraging their safety profile in immunocompromised patients. This taxonomy highlights the interplay between technological maturity and therapeutic innovation: adenoviruses dominate due to scalability, whereas emerging vectors like herpesviruses reflect R&D investment. Manufacturers must balance process optimization for each virus type, influencing service pricing and market accessibility. The segmentation thus reflects both current capabilities and future R&D priorities in oncolytic virotherapy.

Oncolytic Virus Manufacturing Services Segmentation Breakdown9 items

Application

R&D

Biopharmaceutical Manufacturers

Others

Types

Oncolytic Herpes Simplex Virus

Oncolytic Adenovirus

Oncolytic Vaccinia Virus

Others

Regional Insights

Loading chart…

North America dominates the oncolytic virus manufacturing services market with a 40% value share, driven by advanced biopharma infrastructure, high adoption of personalized oncology therapies, and robust R&D investments. The region benefits from a mature ecosystem, including partnerships between key manufacturers and biotech firms, alongside supportive regulatory frameworks accelerating clinical trials.

Europe follows with a 30% share, fueled by stringent cancer treatment policies, EU Horizon funding for gene therapy R&D, and a skilled workforce. Germany and the UK lead in manufacturing scale, supported by cross-border collaborations and public-private initiatives. Adoption rates remain high due to favorable reimbursement models.

Asia Pacific (20% share) is the fastest-growing region, with India and China spearheading expansion through government-funded biotech hubs, rising cancer prevalence, and cost-competitive manufacturing capabilities. Emerging players are investing in infrastructure upgrades to meet global quality standards, positioning the region as a key growth driver in the regional forecast.

Latin America (5%) and Middle East & Africa (5%) remain nascent markets, constrained by limited healthcare budgets and underdeveloped biomanufacturing ecosystems. However, targeted investments in oncology infrastructure and partnerships with global CMOs are unlocking opportunities in Brazil and South Africa, with growth potential tied to improved regulatory alignment.

Competitive Landscape

The Oncolytic Virus Manufacturing Services market exhibits a moderately consolidated structure, with a mix of global biologics CDMOs and niche players specializing in viral vector production. The Oncolytic Virus Manufacturing Services competitive landscape is shaped by players leveraging regulatory expertise, end-to-end process validation, and GMP-certified facilities to differentiate offerings. Pricing pressures remain constrained due to high R&D costs and capital-intensive infrastructure, while partnerships with academic institutions for process optimization and licensing of proprietary manufacturing platforms drive competitive positioning. Global firms dominate large-scale commercial production, whereas regional players focus on flexible, mid-size batches to serve emerging biotech clients.

Competitive strategies emphasize M&A activity to acquire viral vector IP, strategic alliances with gene therapy developers, and localized manufacturing hubs to mitigate supply chain delays. Differentiation hinges on single-use system adoption, modular facility design for rapid scalability, and specialized QC protocols for oncolytic virus purity. A key challenge is balancing compliance with evolving EMA/FDA guidelines while maintaining profit margins amid rising raw material costs. Players also invest in AI-driven process analytical technology to reduce batch failure rates and accelerate time-to-market for client therapies.

Recipharm (Vibalogics): Expansion into EU mid-scale viral vector production

FUJIFILM Diosynth Biotechnologies: Vertical integration of AAV and oncolytic virus workflows

Lonza: OEM tie-ups for end-to-end GMP manufacturing of armed oncolytic viruses

WuXi ATU: Regional expansion in China with dual FDA-EMA certified viral CMO sites

Exothera: Innovation pipeline focused on next-gen CRISPR-based oncolytic platforms

Takara Bio: Premium pricing for closed-system, low-biomolecule-interference manufacturing

Key Oncolytic Virus Manufacturing Services Companies16 items

Recipharm (Vibalogics)

IDT Biologika

FUJIFILM Diosynth Biotechnologies

Exothera

Lonza

Creative Biolabs

Takara Bio

Libentech

ABL

Nabios

Halix

Obio Technology

Porton Advanced

WuXi ATU

Genevoyager

Segens

Market Ecosystem

The Oncolytic Virus Manufacturing Services ecosystem spans upstream technology and raw material inputs, midstream manufacturing execution, and downstream clinical deployment. Value is generated through specialized viral vector production, purification, and quality assurance processes that enable oncology therapies to progress from research to commercialization. This ecosystem is shaped by regulatory compliance, technological innovation, and partnerships between biologics developers and contract manufacturers.

Raw material suppliers — provide cell culture media, viral vectors, and reagents for production

Technology platform providers — license proprietary viral engineering and amplification systems

Contract development and manufacturing organizations (CDMOs) — execute end-to-end oncolytic virus production

Quality assurance/quality control service providers — validate sterility, potency, and viral titer specifications

Clinical logistics partners — manage cold chain distribution of temperature-sensitive biologics

Biopharmaceutical and biotech companies — commission manufacturing for clinical trials and commercial supply

Regulatory agencies — establish guidelines for GMP compliance and therapeutic approval pathways

Control points reside in regulatory agencies and CDMOs with validated manufacturing capabilities, creating bottlenecks during scale-up phases. Raw material availability and technology licensing agreements represent critical dependency risks, while high switching costs for end users reinforce long-term partnerships. Interoperability between production platforms and adherence to evolving viral vector standards further shape ecosystem dynamics.

Recent Industry Insights

The Oncolytic Virus Manufacturing Services industry trends have witnessed transformative advancements over the past 18 months, driven by rising demand for personalized cancer therapies. Key players have prioritized partnerships and expansions to address scalability challenges, with notable collaborations such as Lonza’s alliance with a leading biotech firm to co-develop closed-system manufacturing platforms. Mergers & acquisitions have accelerated, including Takeda’s acquisition of a niche CDMO specializing in adenovirus vector production, strengthening its gene therapy portfolio. Regulatory bodies like the FDA have introduced updated guidelines for viral vector quality control, prompting firms to adopt AI-driven analytics for real-time process monitoring.

Funding rounds reached an all-time high, with startups like Xcell Therapeutics securing $120M in Series C financing to scale modular manufacturing units. Enterprise trends show a shift toward contract manufacturing to de-risk internal R&D pipelines, while technology launches—such as GMP-compliant single-use bioreactors—have improved yield consistency. As the industry moves toward autologous therapies, flexible, small-batch production is emerging as a critical trend. Analysts predict that investments in automation and synthetic biology will redefine cost structures and time-to-market for next-gen oncolytic treatments in 2024.

Analyst Overview

The Oncolytic Virus Manufacturing Services market outlook remains highly attractive, driven by rising demand for personalized cancer therapies and advancements in gene-editing technologies. With market attractiveness bolstered by strong R&D pipelines and favorable reimbursement trends, strategic investments are critical for stakeholders to capitalize on growth opportunities.

Key Insights5 items

Competitive intensity is moderate, with established CDMOs dominating large-scale production but emerging players innovating in niche, high-margin segments.

The long-term outlook is bullish, supported by expanding clinical trials and regulatory approvals, which are projected to scale demand 3–4x by 2030.

Innovation focuses on continuous manufacturing and AI-driven quality control, reducing costs and improving batch consistency.

Demand-supply balance shows tightening capacity constraints, as legacy facilities struggle to meet biologics production needs, creating opportunities for new entrants.

Key risks include high R&D failure rates, stringent regulatory compliance costs, and supply chain fragility for critical raw materials.

11 items

1. Executive Summary

2. Oncolytic Virus Manufacturing Services Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Oncolytic Virus Manufacturing Services Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Oncolytic Virus Manufacturing Services Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. R&D

6.1.2. Biopharmaceutical Manufacturers

6.1.3. Others

6.2. Global Oncolytic Virus Manufacturing Services Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Oncolytic Herpes Simplex Virus

6.2.2. Oncolytic Adenovirus

6.2.3. Oncolytic Vaccinia Virus

6.2.4. Others

6.3. Global Oncolytic Virus Manufacturing Services Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Oncolytic Virus Manufacturing Services Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Oncolytic Virus Manufacturing Services Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Oncolytic Virus Manufacturing Services Market Competition by Key Manufacturers

8.1. Global Oncolytic Virus Manufacturing Services Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Oncolytic Virus Manufacturing Services: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Recipharm (Vibalogics)

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. IDT Biologika

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. FUJIFILM Diosynth Biotechnologies

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Exothera

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Lonza

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Creative Biolabs

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Takara Bio

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Libentech

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. ABL

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Nabios

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Halix

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Obio Technology

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Porton Advanced

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. WuXi ATU

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Genevoyager

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Segens

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Oncolytic Virus Manufacturing Services Market

Figure 4: Global Oncolytic Virus Manufacturing Services Market: Drivers

Figure 5: Global Oncolytic Virus Manufacturing Services Market: Challenges

Figure 6: Global Oncolytic Virus Manufacturing Services Market: Trends

Figure 7: Global Oncolytic Virus Manufacturing Services Market: Opportunity

Figure 8: Global Oncolytic Virus Manufacturing Services Market: Restraint

Figure 9: Global Oncolytic Virus Manufacturing Services Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Oncolytic Virus Manufacturing Services Market Value (USD Million) By Region

Figure 15: Global Oncolytic Virus Manufacturing Services Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Oncolytic Virus Manufacturing Services Market Value (USD Million) By Region

Figure 23: Global Oncolytic Virus Manufacturing Services Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global Oncolytic Virus Manufacturing Services Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Oncolytic Virus Manufacturing Services Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Oncolytic Virus Manufacturing Services Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Oncolytic Virus Manufacturing Services Market Value (USD Million) By Region

Table 10: Global Oncolytic Virus Manufacturing Services Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Oncolytic Virus Manufacturing Services Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Oncolytic Virus Manufacturing Services Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Oncolytic Virus Manufacturing Services Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Recipharm (Vibalogics) Basic Information And Sales Area

Table 31: Recipharm (Vibalogics). Products Portfolio

Table 32: IDT Biologika Basic Information And Sales Area

Table 33: IDT Biologika. Products Portfolio

Table 34: FUJIFILM Diosynth Biotechnologies Basic Information And Sales Area

Table 35: FUJIFILM Diosynth Biotechnologies. Products Portfolio

Table 36: Exothera Basic Information And Sales Area

Table 37: Exothera. Products Portfolio

Table 38: Lonza Basic Information And Sales Area

Table 39: Lonza. Products Portfolio

Table 40: Creative Biolabs Basic Information And Sales Area

Table 41: Creative Biolabs. Products Portfolio

Table 42: Takara Bio Basic Information And Sales Area

Table 43: Takara Bio. Products Portfolio

Table 44: Libentech Basic Information And Sales Area

Table 45: Libentech. Products Portfolio

Table 46: ABL Basic Information And Sales Area

Table 47: ABL. Products Portfolio

Table 48: Nabios Basic Information And Sales Area

Table 49: Nabios. Products Portfolio

Table 50: Halix Basic Information And Sales Area

Table 51: Halix. Products Portfolio

Table 52: Obio Technology Basic Information And Sales Area

Table 53: Obio Technology. Products Portfolio

Table 54: Porton Advanced Basic Information And Sales Area

Table 55: Porton Advanced. Products Portfolio

Table 56: WuXi ATU Basic Information And Sales Area

Table 57: WuXi ATU. Products Portfolio

Table 58: Genevoyager Basic Information And Sales Area

Table 59: Genevoyager. Products Portfolio

Table 60: Segens Basic Information And Sales Area

Table 61: Segens. Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Types

Table 65: Global Market Share (%) By Types (2032)

Table 66: Global Oncolytic Virus Manufacturing Services Market Value (USD Million) By Region

Table 67: Global Oncolytic Virus Manufacturing Services Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: North America Market Value (USD Million) (2025-2032) By Types

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Europe Market Value (USD Million) (2025-2032) By Types

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: South America Market Value (USD Million) (2025-2032) By Types

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Oncolytic Virus Manufacturing Services Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.80 billion
Growth rate	CAGR of 15.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Recipharm (Vibalogics); IDT Biologika; FUJIFILM Diosynth Biotechnologies; Exothera; Lonza; Creative Biolabs; Takara Bio; Libentech; ABL; Nabios; Halix; Obio Technology; Porton Advanced; WuXi ATU; Genevoyager; Segens
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options